

RECEIVED  
CENTRAL FAX CENTER

NOV 16 2006


2

Docket No. UF-340XC1  
Serial No. 10/731,528In the Claims:

This listing of claims will replace all prior versions and listings of claims in this application.

1-5 (canceled).

6 (previously presented). A method for treating a patient diagnosed with at least one ophthalmic disorder, wherein said method comprises administering to the patient an effective amount of a steroidal quinol that is converted to a biologically active phenolic A-ring steroid compound *in vivo*, wherein the steroidal quinol has the general structure:



7 (canceled).

8 (previously presented). The method, according to claim 6, further comprising administering the quinol by a route selected from the group consisting of oral, topical, buccal, intramuscular, transdermal, intravenous, and subcutaneous.

9 (previously presented). The method, according to claim 6, wherein the ophthalmic disorders are selected from the group consisting of conjunctivitis, diabetic retinopathy, dry eye, macular degeneration, glaucoma, and cataracts.


10-12 (canceled)

J:\uf340xc1\F-Amend.doc1a

3

Docket No. UF-340XC1  
Serial No. 10/731,528

13 (previously presented). A method for treating a patient diagnosed with at least one ophthalmic disorder, wherein said method comprises administering to the patient an effective amount of a steroidal quinol that is converted to a biologically active phenolic A-ring steroid compound *in vivo*, wherein the quinol has the general structure:



14 (previously presented). The method, according to claim 13, further comprising administering the quinol by a route selected from the group consisting of oral, topical, buccal, intramuscular, transdermal, intravenous, and subcutaneous.

15 (previously presented). The method, according to claim 13, wherein the ophthalmic disorders are selected from the group consisting of conjunctivitis, diabetic retinopathy, dry eye, macular degeneration, glaucoma, and cataracts.

16 (previously presented). A method for treating a patient diagnosed with at least one ophthalmic disorder, wherein said method comprises administering to the patient an effective amount of a steroidal quinol that is converted to a biologically active phenolic A-ring steroid compound *in vivo*, wherein the steroidal quinol is 2-(1-adamantyl)-10β-hydroxyestra-1,4-diene-3,17-dione.

17-20 (canceled).

J:\uf\340xc\VF-Amend.doc1a

4

Docket No. UF-340XC1  
Serial No. 10/731,528

21 (currently amended). A steroidal quinol that ~~consists of~~ is 2-(1-adamantyl-10 $\beta$ -hydroxyestra-1,4-diene-3,17-dione.

22 (previously presented). A pharmaceutical composition comprising 2-(1-adamantyl-10 $\beta$ -hydroxyestra-1,4-diene-3,17-dione.

23 (previously presented). The method, according to claim 8, wherein the steroidal quinol is administered topically in the form of eye drops or membranous ocular eye patch.

24 (canceled).

25 (previously presented). The method, according to claim 14, wherein the steroidal quinol is administered topically in the form of eye drops or membranous ocular eye patch.

J:\uf340xc1\F-Amend.dod\la